MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock from atm...
$1,994,374
Net cash provided by
financing activities
$1,903,022
Canceled cashflow
$91,352
Net increase
(decrease) in cash and cash...
-$576,696
Canceled cashflow
$1,903,022
Stock-based compensation
$43,278
Payment of issuance
costs
$91,352
Net cash used in
operating activities
-$2,479,718
Canceled cashflow
$43,278
Interest income
$78,676
Net loss
-$1,847,706
Accrued and other
current liabilities
-$445,640
Inventory
$93,091
Prepaid expenses and
other current assets
$85,431
Accounts payable
-$51,128
Canceled cashflow
$78,676
Total selling,
general and...
$1,542,658
Total research and
development
$383,724
Back
Back
Cash Flow
Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc. (DRMA)
source: myfinsight.com